MOLOGEN AG
MOLOGEN AG: Three poster presentations at ESMO 2014 Congress
MOLOGEN AG / Key word(s): Conference/Study MOLOGEN AG: Three poster presentations at ESMO 2014 Congress Berlin, September 18, 2014 – Two posters on clinical trials with the cancer immune therapy MGN1703 and one with the therapeutic cancer vaccine MGN1601 of the biotechnology company MOLOGEN AG have been accepted at the ESMO Congress in Madrid (September 26 – 30, 2014). Updated data on patients with long-term progression-free survival from the phase II IMPACT trial with MGN1703 in colorectal cancer will be presented. In addition, a second poster will be featured on the design of IMPALA, the subsequent pivotal study. Furthermore, final results of the ASET trial with MGN1601 in heavily pretreated patients with advanced renal cancer will be shown. Poster details: 1061P – IMPACT study: A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703 1077TiP – Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal carcinoma – the randomized phase 3 IMPALA study 1063P – ASET study: Final results of patients with locally recurrent or metastatic renal cell carcinoma (RCC) treated with MGN1601 For more information on the ESMO please visit ESMO’s website www.esmo.org. For more information on the IMPALA, IMPACT and ASET trials please visit www.clinicaltrials.gov. About MGN1703 About MGN1601 About MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). Second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. www.mologen.com Memberships in associations: MOLOGEN AG Note about risk for future predictions 18.09.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
287555 18.09.2014 |